Insider Selling: Jason Rhodes Unloads 10,000 Shares of Epizyme Stock (EPZM)
Epizyme (NASDAQ:EPZM) CFO Jason Rhodes unloaded 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.19, for a total transaction of $201,900.00. Following the completion of the sale, the chief financial officer now directly owns 4,000 shares in the company, valued at approximately $80,760. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Epizyme in a research note to investors on Friday, November 15th. They now have a $32.00 price target on the stock, down previously from $42.00. Five research analysts have rated the stock with a buy rating, Epizyme currently has an average rating of “Buy” and a consensus target price of $34.50.
Epizyme (NASDAQ:EPZM) traded down 0.34% during mid-day trading on Monday, hitting $20.50. The stock had a trading volume of 136,060 shares. Epizyme has a 52 week low of $18.10 and a 52 week high of $45.72. The stock has a 50-day moving average of $20.9 and a 200-day moving average of $30.96. The company’s market cap is $582.4 million.
Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.